What is Faeth Therapeutics?
Faeth Therapeutics is a clinical-stage biotechnology company that has developed a proprietary AI-driven platform, MetabOS, designed to identify and exploit metabolic dependencies in cancer cells. This innovative approach allows the company to develop multi-node therapies that simultaneously block cancer growth signals and control the tumor's fuel supply. Beyond its core oncology applications, Faeth Therapeutics is also extending its platform's utility to rare diseases, with a notable translational program in Hereditary Tyrosinemia Type 1 (HT1). Founded in 2019, the company is poised to leverage its unique metabolic targeting strategy for broad therapeutic impact.
How much funding has Faeth Therapeutics raised?
Faeth Therapeutics has raised a total of $92M across 3 funding rounds:
Angel/Seed
$20M
Series A
$47M
Other Financing Round
$25M
Angel/Seed (2022): $20M with participation from S2G Ventures, Khosla Ventures, and Future Ventures
Series A (2022): $47M led by Future Ventures, Khosla Ventures, and S2G Ventures
Other Financing Round (2025): $25M supported by S2G Ventures, Digitalis Ventures, Future Technologies, and Khosla Ventures
Key Investors in Faeth Therapeutics
Future Ventures
Future Ventures is a venture capital firm that supports mission-driven founders who are forging the future by backing visionary entrepreneurs with unique ideas. They focus on seed and early-stage investments in purpose-driven individuals who have the potential to reinvent industries.
Khosla Ventures
Khosla Ventures provides venture assistance and strategic advice to entrepreneurs working on breakthrough technologies. The firm was founded in 2004 by Vinod Khosla, co-founder of Sun Microsystems.
S2G Ventures
S2G Ventures (Seed 2 Growth) is a multi-stage food and agriculture venture fund investing in entrepreneurs whose products and services meet the shifting demands for healthy and sustainable food.
What's next for Faeth Therapeutics?
With a substantial enterprise-level funding injection and a recent strategic investment, Faeth Therapeutics is well-positioned to accelerate its development pipeline. The company's focus on advancing multiple solid-tumor studies and its pioneering work in rare diseases indicate a strategic expansion of its therapeutic reach. The backing from prominent investors suggests confidence in Faeth's AI-driven MetabOS platform and its potential to disrupt both oncology and metabolic disease treatment paradigms. Future capital allocation will likely prioritize clinical trial progression, platform enhancement, and potential expansion into new therapeutic areas.
See full Faeth Therapeutics company page
